1
|
Lomov NA, Viushkov VS, Rubtsov MA. Mechanisms of Secondary Leukemia Development Caused by Treatment with DNA Topoisomerase Inhibitors. BIOCHEMISTRY. BIOKHIMIIA 2023; 88:892-911. [PMID: 37751862 DOI: 10.1134/s0006297923070040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 04/14/2023] [Accepted: 04/20/2023] [Indexed: 09/28/2023]
Abstract
Leukemia is a blood cancer originating in the blood and bone marrow. Therapy-related leukemia is associated with prior chemotherapy. Although cancer therapy with DNA topoisomerase II inhibitors is one of the most effective cancer treatments, its side effects include development of secondary leukemia characterized by the chromosomal rearrangements affecting AML1 or MLL genes. Recurrent chromosomal translocations in the therapy-related leukemia differ from chromosomal rearrangements associated with other neoplasias. Here, we reviewed the factors that drive chromosomal translocations induced by cancer treatment with DNA topoisomerase II inhibitors, such as mobility of ends of double-strand DNA breaks formed before the translocation and gain of function of fusion proteins generated as a result of translocation.
Collapse
Affiliation(s)
- Nikolai A Lomov
- Department of Molecular Biology, Faculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia.
| | - Vladimir S Viushkov
- Department of Molecular Biology, Faculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia
| | - Mikhail A Rubtsov
- Department of Molecular Biology, Faculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia
- Department of Biochemistry, Center for Industrial Technologies and Entrepreneurship Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119435, Russia
| |
Collapse
|
2
|
Shmakova A, Lomov N, Viushkov V, Tsfasman T, Kozhevnikova Y, Sokolova D, Pokrovsky V, Syrkina M, Germini D, Rubtsov M, Vassetzky Y. Cell models with inducible oncogenic translocations allow to evaluate the potential of drugs to favor secondary translocations. CANCER COMMUNICATIONS (LONDON, ENGLAND) 2022; 43:154-158. [PMID: 36250318 PMCID: PMC9859728 DOI: 10.1002/cac2.12370] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 07/21/2022] [Accepted: 10/02/2022] [Indexed: 01/26/2023]
Affiliation(s)
- Anna Shmakova
- UMR9018Université Paris‐SaclayCentre national de la recherche scientifique, Gustave RoussyVillejuif94805France,Koltzov Institute of Developmental BiologyRussian Academy of SciencesMoscow119334Russia,Institute of Experimental CardiologyNational Medical Research Centre of CardiologyMoscow121552Russia
| | - Nikolai Lomov
- UMR9018Université Paris‐SaclayCentre national de la recherche scientifique, Gustave RoussyVillejuif94805France,Department of Molecular BiologyFaculty of BiologyLomonosov Moscow State UniversityLeninskie GoryMoscow119991Russia
| | - Vladimir Viushkov
- Department of Molecular BiologyFaculty of BiologyLomonosov Moscow State UniversityLeninskie GoryMoscow119991Russia
| | - Tatyana Tsfasman
- UMR9018Université Paris‐SaclayCentre national de la recherche scientifique, Gustave RoussyVillejuif94805France
| | - Yana Kozhevnikova
- UMR9018Université Paris‐SaclayCentre national de la recherche scientifique, Gustave RoussyVillejuif94805France,Faculty of MedicineLomonosov Moscow State UniversityMoscow119991Russia
| | - Darina Sokolova
- Laboratory of Combined TreatmentBlokhin Cancer Research CenterMoscow115478Russia,Department of BiochemistryPeoples’ Friendship University of RussiaMoscow117198Russia,Center of Genetics and Life SciencesSirius University of Science and TechnologyFederal Territory SiriusSochi354340Russia
| | - Vadim Pokrovsky
- Laboratory of Combined TreatmentBlokhin Cancer Research CenterMoscow115478Russia,Department of BiochemistryPeoples’ Friendship University of RussiaMoscow117198Russia,Center of Genetics and Life SciencesSirius University of Science and TechnologyFederal Territory SiriusSochi354340Russia
| | - Marina Syrkina
- Department of Molecular BiologyFaculty of BiologyLomonosov Moscow State UniversityLeninskie GoryMoscow119991Russia
| | - Diego Germini
- UMR9018Université Paris‐SaclayCentre national de la recherche scientifique, Gustave RoussyVillejuif94805France
| | - Mikhail Rubtsov
- Department of Molecular BiologyFaculty of BiologyLomonosov Moscow State UniversityLeninskie GoryMoscow119991Russia,Department of BiochemistryCenter for Industrial Technologies and EntrepreneurshipSechenov First Moscow State Medical UniversityMoscow119991Russia
| | - Yegor Vassetzky
- UMR9018Université Paris‐SaclayCentre national de la recherche scientifique, Gustave RoussyVillejuif94805France,Koltzov Institute of Developmental BiologyRussian Academy of SciencesMoscow119334Russia
| |
Collapse
|
3
|
Recurrent Translocations in Topoisomerase Inhibitor-Related Leukemia Are Determined by the Features of DNA Breaks Rather Than by the Proximity of the Translocating Genes. Int J Mol Sci 2022; 23:ijms23179824. [PMID: 36077220 PMCID: PMC9456246 DOI: 10.3390/ijms23179824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2022] [Revised: 08/09/2022] [Accepted: 08/21/2022] [Indexed: 11/25/2022] Open
Abstract
Topoisomerase inhibitors are widely used in cancer chemotherapy. However, one of the potential long-term adverse effects of such therapy is acute leukemia. A key feature of such therapy-induced acute myeloid leukemia (t-AML) is recurrent chromosomal translocations involving AML1 (RUNX1) or MLL (KMT2A) genes. The formation of chromosomal translocation depends on the spatial proximity of translocation partners and the mobility of the DNA ends. It is unclear which of these two factors might be decisive for recurrent t-AML translocations. Here, we used fluorescence in situ hybridization (FISH) and chromosome conformation capture followed by sequencing (4C-seq) to investigate double-strand DNA break formation and the mobility of broken ends upon etoposide treatment, as well as contacts between translocation partner genes. We detected the separation of the parts of the broken AML1 gene, as well as the increased mobility of these separated parts. 4C-seq analysis showed no evident contacts of AML1 and MLL with loci, implicated in recurrent t-AML translocations, either before or after etoposide treatment. We suggest that separation of the break ends and their increased non-targeted mobility—but not spatial predisposition of the rearrangement partners—plays a major role in the formation of these translocations.
Collapse
|
4
|
Chauhan P, Gupta A, Panambur CB, Chandra D, Kashyap R. Acute Promyelocytic Leukemia Masquerading as Sero-negative Polyarthritis: Case Report. Indian J Med Paediatr Oncol 2022. [DOI: 10.1055/s-0042-1743506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
Abstract
AbstractMusculoskeletal manifestations as the sole presentation in acute leukemia is rare in adults. Acute promyelocytic leukemia (APML) is a subtype of acute myeloid leukemia (AML) with reported incidence of 10 to 15% of total AML cases. APML presenting as polyarticular arthritis has never been reported in the literature. We present an interesting case of 20-year-old male patient who manifested with polyarticular arthritis mainly of small joints as the initial presentation, followed by pancytopenia and eventually was diagnosed as a case of APML on bone marrow morphology and molecular analysis for PML-RARα transcript. He was successfully treated with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). Arthritis also resolved with complete remission of APML. Arthritis in a case with pancytopenia should promptly be evaluated prior to treatment with steroids and anti-metabolites. Arthritis can be a presenting manifestation of APML and responds to prompt management of leukemia as in other cases of leukemic arthritis.
Collapse
Affiliation(s)
- Priyanka Chauhan
- Department of Haematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
| | - Anshul Gupta
- Department of Haematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
| | - Chandni Bhandary Panambur
- Department of Haematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
| | - Dinesh Chandra
- Department of Haematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
| | - Rajesh Kashyap
- Department of Haematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
| |
Collapse
|
5
|
Bayrak AG, Ucur A, Daglar Aday A, Bagatır G, Erdem S, Hancer VS, Nalcacı M, Ozturk S, Cefle K, Palanduz S, Yavuz AS. A case mimicking chronic myeloid leukemia with t(8;22)(p11;q11)/BCR-FGFR1 and sequential transformation to B-acute lymphoblastic leukemia and acute myeloid leukemia. J Hematop 2021. [DOI: 10.1007/s12308-020-00429-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
|
6
|
Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis. Ann Hematol 2019; 98:2841-2843. [PMID: 31728617 DOI: 10.1007/s00277-019-03838-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 10/28/2019] [Indexed: 01/25/2023]
|
7
|
Li Y, Liu Q, Wang Z, Qin YZ, Dang H, Shi Y, He Q, Jiang Q, Jiang H, Lai YY. [Clinical analysis of myeloid neoplasms with t (3;21) (q26;q22)]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 40:195-199. [PMID: 30929385 PMCID: PMC7342542 DOI: 10.3760/cma.j.issn.0253-2727.2019.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
目的 探讨伴有t(3;21)(q26;q22)髓系肿瘤的临床特征。 方法 回顾性分析2011年1月至2018年3月北京大学人民医院收治的19例伴有t(3;21)(q26;q22)血液恶性肿瘤患者的临床资料,并汇总文献报道的有详细生存资料的48例患者,采用Kaplan-Meier法进行生存分析。 结果 19例患者中男15例,女4例,中位年龄36(22~68)岁,包括原发急性髓系白血病(AML)4例,骨髓增生异常综合征(MDS)4例,MDS转化的AML3例,慢性髓性白血病(CML)急变8例。19例患者染色体核型均可见t(3;21)(q26;q22),其中13例伴有附加异常。19例中9例进行AML1-MDS1融合基因检测均阳性。9例患者有随访资料,6例接受化疗的患者中4例无效,2例获得完全缓解。随访期内除1例MDS患者因随访期短(6个月)仍存活,其余8例均死亡,中位生存时间为6(4.5~22)个月。汇总文献生存分析结果显示伴有t(3;21)(q26;q22)的髓系肿瘤患者整体预后差,中位生存时间为7个月,尤以AML/治疗相关的AML预后最差,移植和非移植组中位生存时间分别为20.9和4.7个月,差异有统计学意义(P<0.001)。 结论 t(3;21)(q26;q22)是罕见的重现性染色体异常,主要见于髓系血液肿瘤,临床预后差,建议尽早进行造血干细胞移植。
Collapse
Affiliation(s)
- Y Li
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Jayashree S, Nirekshana K, Guha G, Bhakta-Guha D. Cancer chemotherapeutics in rheumatoid arthritis: A convoluted connection. Biomed Pharmacother 2018; 102:894-911. [PMID: 29710545 DOI: 10.1016/j.biopha.2018.03.123] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 03/20/2018] [Accepted: 03/20/2018] [Indexed: 12/11/2022] Open
Abstract
Chemotherapy is one of the most popular therapeutic strategies to treat cancer. However, cancer chemotherapeutics have often been associated with impairment of the immune system, which might consequently lead to an augmented risk of autoimmune disorders, such as rheumatoid arthritis. Though the accurate mechanistic facets of rheumatoid arthritis induction have not been interpreted yet, a conglomeration of genetic and environmental factors might promote its etiology. What makes the scenario more challenging is that patients with rheumatoid arthritis are at a significantly elevated risk of developing various types of cancer. It is intriguing to note that diverse cancer chemotherapy drugs are also commonly used to treat symptoms of rheumatoid arthritis. However, a colossal multitude of such cancer therapeutics has demonstrated highly varied results in rheumatoid arthritis patients, including both beneficial and adverse effects. Herein, we attempt to present a holistic account of the variegated modalities of this complex tripartite cross-talk between cancer, rheumatoid arthritis and chemotherapy drugs in order to decode the sinuous correlation between these two appalling pathological conditions.
Collapse
Affiliation(s)
- S Jayashree
- Cellular Dyshomeostasis Laboratory (CDHL), Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, 613 401, Tamil Nadu, India
| | - K Nirekshana
- Cellular Dyshomeostasis Laboratory (CDHL), Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, 613 401, Tamil Nadu, India
| | - Gunjan Guha
- Cellular Dyshomeostasis Laboratory (CDHL), Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, 613 401, Tamil Nadu, India.
| | - Dipita Bhakta-Guha
- Cellular Dyshomeostasis Laboratory (CDHL), Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, 613 401, Tamil Nadu, India.
| |
Collapse
|
9
|
Han Q, Lu J, Wang J, Ye J, Jiang X, Chen H, Liu C, Chen L, Lin T, Chen S, Sun M, Gao F. H2AFY is a novel fusion partner of MECOM in acute myeloid leukemia. Cancer Genet 2018; 222-223:9-12. [PMID: 29666008 DOI: 10.1016/j.cancergen.2018.01.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2017] [Revised: 01/31/2018] [Accepted: 01/31/2018] [Indexed: 11/15/2022]
Abstract
The MECOM gene encoding a zinc finger protein that functions as a transcription factor, was located on chromosome 3q26, and rearrangements of MECOM often cause its overexpression in acute myeloid leukemia (AML). We identified H2AFY as a novel fusion gene partner of MECOM in an elderly male AML patient with cryptic 3q26 rearrangement using the whole transcriptome sequencing, who carried out abnormal karyotype of 46,XY,t(3;5)(q27;q31),add(14)(p11). We validated the existence of the unreported H2AFY-MECOM fusion gene by RT-PCR and Sanger DNA sequencing, and detected mutations of NRAS and BCOR in this patient. In addition, we found abnormally elevated expression of MECOM in this patient by quantitative-polymerase chain reaction (RQ-PCR). Further research is needed to investigate functional characterizations of this novel fusion in the development of AML.
Collapse
Affiliation(s)
- Qiaoyan Han
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Jiao Lu
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Jianjiang Wang
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Jinsong Ye
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Xin Jiang
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Haoyue Chen
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Chunhua Liu
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Lu Chen
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Tong Lin
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Suning Chen
- Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
| | - Miao Sun
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| | - Feng Gao
- Department of Haematology, Jingjiang People's Hospital, the Seventh Affiliated Hospital of Yangzhou University, Jingjiang, Jiangsu, China.
| |
Collapse
|